We would love to hear your thoughts about our site and services, please take our survey here.
I don't think it's possible for it to be Surescreen.
The government tender prohibited nasopharyngeal tests. It has to be anterior nasal or saliva.
Lifted this directly from Surescreens website:
*A swab is used to sample from either the nose or throat (nasopharyngeal or oropharyngeal sample) and introduced into the test cassette by suspension in a buffer solution."
Therefore IMO, Surescreen are out of the running.
Mfm, of course there's more risk with Avacta! ODX and Abingdon are manufacturers. They will have something to manufacture, whatever test it may be.
But there's MUCH more upside with Avacta. ODX and Abingdon upside is limited by their individual manufacturing capacity. Avacta can potentially have their tests made by multiple manufacturers across the globe. You're comparing an apple with a crate of oranges.
We know that Affimer reagents can be produced on scale, so that's the only limiting factor along with availability of raw materials.
Even if Avacta make a test which is a few percent lower on S and S... If it's the fastest test to produce on mass because of reagent availability then it will take the market share.
Some of you may recall the early days of Covid when reagent availability was a problem, so this has already happened and isn't just a work of fiction.
Furthermore.... The problem is with buying Omega and Abingdon is that mass testing will have a finite lifespan. Do either of those companies have a future prospect which is bigger than the Covid-19 testing opportunity? Not that I'm aware of. There will surely be a big sell off in both eventually.
Avacta however.... Well the party is only just getting started...
With Lateral flow test "pre-scale up production testing with selected UK manfufacturers" due to be completed by 31st January, it seems likely something significant is going to happen within the next two weeks.
Whether this is good or bad depends on whether BBI / Abingdon are one of the "selected UK manfacturers" - of course, the more interesting one being BBI as we understand they've had some notable involvement in re-designing our test, as per RNS.
It would seem reasonable to believe that due to it's size, BBI would be one of these mentioned manufacturers, especially due to being part of the UK-RTC - so we know a link to the UK Gov is pre-existing.
IMO it would also seem reasonable to believe that BBI wouldn't have gone to the trouble and expense of re-designing our test if they had something much better to manufacture instead.
For now, all we can do is join the dots. However, I very much think there will be news in the next two weeks, and that said news will be very exciting.
Could be Excalibur as that was approved for mass screening on 12th, on asymptomatic and on pre symptomatic also.
Interesting in that it was validated by lstm... So that's potentially a good sign for us I hope.
Of course, it's one thing having a good test. Being able to make enough of them is an equally big problem to overcome.
Pigster, that's interesting - but I can see it being many more than 27%
I think the vaccine will have a partly self cancelling effect, as with masks.
I believe masks work, but I don't beleive they achieve anything when used by the public due to the sense of safety they give. Before masks were introudced, people would keep their distance. It was very noticeable in day to day thinks like going into the supermarket. However, once everybody had masks on social distancing went largely out the window. There's only a minority who make a real effort to keep away now - from what I see at least (anecdotal of course).
The AZ vaccine is 62% effacious. But people are going to 'feel' like they are 100% percent protected and start to go about their lives more normally, thinking they can't catch it. Personally, based on what I've seen with the masks - I think saying 27% will immediately act as though they are protected is a wild under estimation. In my opinion it will be the marjority. This will offset a lot of the progress made by vaccination.
On a similar not, my grandmother had the Pfizer jab last week. I asked her when her second dose was booked for. She has been told they don't know... probably March because they are really busy. WHO say it should be given within 21 to 28 days of the first jab and recommending that other countries do not follow the UK's approach in an attempt to speed up the roll out.
It's naso, so not competition to us and only CE marked for professional use.
"The Panodyne SARS-COV-2 Antigen Rapid Test Kit uses a specially designed swab that is inserted into the nostril and mouth to take samples from the nasal cavity and tonsils. Measuring just 15cm, the Panodyne Antigen test kit is less invasive than other tests available. "
Have just averaged down on the dip.
It's absolutely glorious watching this. I'm approaching 100 percent up.
The breakout and move up happened as predicted. Much nicer to be at this level now.
For my next prediction... If anybody fancies dabbling in a bit of trading, the ascending triangle pattern on ncyt is looking very interesting. IME it's the most reliable pattern, plus good fundamentals, odds are stacked favourably on that one. Looking for a break and hold above 910 ish over there. Then if it goes well you can buy more AVCT ;)
47,000 isn't exactly a 'large' buy IMO. II's taking positions or increasing holdings if interesting, but I have no interest in what are most likely just PI trades who only have access to the same information as us.
My shares here are worth what some people would earn in a year, but for others only as much as they spend to take their family on a fancy holiday or to put fuel in their yacht for a week.
The size of a trade is relevant to the person's capital. If you're sat on a million quid you might invest 47k as a punt with little research.
If your investing 470 quid its everything you have in the bank, you're probably going to make sure you know the share inside out.
Furthermore, in my experience, a persons wealth is not always directly proportionate to their intellect...
I bet there's a lot of people reading this board who are following the research of other investors who actually have a significantly smaller holding than them.
I have nothing useful to add to the chat here, but just thought I would pop my head in the door and say I completely agree. I bought more ncyt this morning and I'm looking forward to seeing the numbers and the resulting cash position.
Slipping share price is just impatient holders imo. No doubt they will regret selling.
Regardless, there seems to be resistance at this level so can't see it will go lower... Hence my little top up.
That 60p will be back soon enough no doubt. I just can't see there's any downside from this level unless there's some left field bad news.
Even without an RNS, it will probably break out. Set your chart to 4hr and have a look at the triangle pattern which is forming. You don't need to draw it, it's very clear to see. The consolidation should continue, likely resulting in a technical breakout within the next few trading sessions...
Meanwhile, back in the real world...
"Oxford/AstraZeneca had 62% efficacy in their largest trial, of 11,636 people, but 90% efficacy in a small additional sub-group in the UK numbering 2,741 who were given a half dose of the vaccine, followed by a whole dose four weeks later."
And none of the sub group were aged over 55.
Even though az vaccine wasn't unexpected news to anybody, I'm surprised at the resilience of the share price this morning! Low is currently 108.5. Before Christmas I was expecting to see this drop to around 104.
Panic selling appears to be minimal.